Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Triptans for migraine headaches: a review of clinical evidence on safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions While no consistent differences were found between triptans in the rates of overall adverse events (AEs), a small number of studies suggest oral, intranasal and subcutaneous sumatriptan are associated with chest pain and tachycardia. The most common AEs include dizziness, drowsiness, paresthesia, nausea and fatigue. One study suggests that providing a clinical limit of 27 rizatriptan ODT 10 mg/month did not reduce the number of migraine days compared with providing a formulary limit of 9 tablets per month. Regardless of quantity, rizatriptan ODT 10 mg was well tolerated as AEs were similar between groups. Indexing Status Subject indexing assigned by CRD MeSH Analgesics; Migraine Disorders; Tryptaminess Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: htainfo@cadth.ca AccessionNumber 32012000662 Date abstract record published 26/09/2012 |